Please login to the form below

Not currently logged in


This page shows the latest NASH news and features for those working in and with pharma, biotech and healthcare.

Gilead NASH drug clears mid-stage trial, but rivals are looming

Gilead NASH drug clears mid-stage trial, but rivals are looming

Gilead NASH drug clears mid-stage trial, but rivals are looming. Positive results to challenge Intercept in emerging disease area. ... is already on the market for primary biliary cirrhosis (PBC) and in phase 3 for NASH patients with cirrhosis.

Latest news

More from news
Approximately 10 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    treatments for NASH with Pfizer products. Not. disclosed. One of the big deals for Novartis these last two months was the long‐ rumoured sale of it’s Sandoz division’s US ... The agreement is driven by the belief that liver diseases will respond

  • Taking a lean and careful approach Taking a lean and careful approach

    A lot of NASH patients also have these conditions so we want to look at and understand the underlying causes to see what else we can come up with there.”. ... The NASH market is expected to be worth $20bm by 2025 and financial brokers recently valued

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Oncology, immuno-oncology and central nervous system therapies once again topped the charts, but 2016 also saw the emergence of new areas, notably non-alcoholic steatohepatitis or NASH. ... With NASH appearing to be a long-term consequence of obesity it

  • Deal Watch December 2016 Deal Watch December 2016

    The Scandinavian company, Nuevolution, uses its drug discovery platform Chemetics to discover novel small molecules in the field of chronic inflammatory diseases, including psoriasis, rheumatoid arthritis, non-alcoholic steato-hepatitis (NASH),

  • Deal Watch September 2016 Deal Watch September 2016

    Taking advantage of the drop in Tobira's market cap following disappointing results from the phase IIb studies in NASH, Allergan still paid a significant amount to secure the business with ... This acquisition brings a phase I oral DPP 4, evogliptin, and

More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...